EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Human immunodeficiency virus sexual risk reduction in homeless men with mental illness






Archives of General Psychiatry 55(3): 266-272

Human immunodeficiency virus sexual risk reduction in homeless men with mental illness

Background: The spread of human immunodeficiency virus infection to impaired groups has intensified the challenge for its prevention; control of the epidemic now requires behavioral change among persons with limited ability to sustain attention and learn. In this randomized clinical trial, we tested an intervention to reduce sexual risk behaviors among homeless men with severe mental illness. Methods: Men were recruited from a psychiatric program in a homeless shelter. Of 116 eligible men, 97 (83.6%) participated. Most were African American and had a chronic psychotic disorder and a comorbid substance use disorder. Participants were assigned to a 15-session experimental group intervention or to a 2-session control intervention and observed for 18 months. The 59 participants sexually active before the trial were the main target of the intervention. Sexual risk behavior was the primary outcome. Results: Among the 59 sexually active men, follow-up data were obtained on 59 (100%) for the initial 6-month follow-up and on 56 (95%) for the remainder of the 18-month follow-up. The mean score on a sexual risk index for the experimental group was 3 times lower than for the control group (1.0 vs 3.1; p=.01) during the initial 6-month follow-up and 2 times lower during the remainder of the 18-month follow-up. Conclusions: This intervention successfully reduced sexual risk behaviors of homeless men with mental illness. The effect diminished over 18 months but did not disappear. Similar approaches may be effective in other impaired high-risk groups.


Accession: 003162899

PMID: 9510221

DOI: 10.1001/archpsyc.55.3.266



Related references

Determinants of risk behavior for human immunodeficiency virus/acquired immunodeficiency syndrome in people with severe mental illness. Comprehensive Psychiatry 42(4): 263-271, 2001

Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Comprehensive Psychiatry 44(4): 293-302, 2003

Interventions for homeless men and women with mental illness: reducing sexual risk behaviours for HIV. International Journal of Std & Aids 7 Suppl 2: 66-70, 1996

Reliability of self-reports about sexual risk behavior for HIV among homeless men with severe mental illness. Psychiatric Services 51(6): 814-816, 2000

Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. Pharmacology & Therapeutics 124(3): 269-278, 2010

Efficacy of sexually transmitted disease/human immunodeficiency virus sexual risk-reduction intervention for african american adolescent females seeking sexual health services: a randomized controlled trial. Archives of Pediatrics & Adolescent Medicine 163(12): 1112-1121, 2010

The impact of substance dependence on HIV sexual risk-reduction among men with severe mental illness. Aids Care 17(5): 635-639, 2005

Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexual transmitted diseases: A randomized controlled trial. JAMA (Journal of the American Medical Association) 280(13): 1161-1167, Oct 7, 1998

HIV, STD, and Sexual Risk Reduction for Individuals with a Severe Mental Illness: Review of the Intervention Literature. Current Psychiatry Reviews 4(2): 87-100, 2008

Sexual Risk Reduction for Patients with Mental Illness: Evidence of Efficacy and Reasons for Hope. Current Infectious Disease Reports 7(2): 85-86, 2005